Disclosed here is a pharmaceutical composition comprising deferasirox in the form of particles, wherein the particles have an average particle size of less than or equal to about 2000 nm.

The present invention discloses Pharmaceutical Compounds comprising dipeptidyl peptidase-4 (DPP-4) inhibitor and meglitinides, processes for preparation of the same and their uses as medicaments or in pharmaceutical composition, more particularly for the treatment of Type 2 diabetes. The Pharmaceutical Compound may ...

The present invention relates to a crystalline polymorphic form of 6-fluoro-1-methyl-7- {4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl}-4-oxo-4H-[1,3]-thiazeto-[3,2- a]-quinoline-3-carboxylic acid (prulifloxacin). More specifically, the invention relates to a crystalline form of prulifloxacin (herein refe...

There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R" is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-...

There is provided a process for the preparation of sitagliptin or a pharmaceutically acceptable salt thereof and a process for the preparation of intermediate compounds useful in the preparation of sitagliptin. In particular there is provided a process comprising condensing 3 tert butoxycarbonylamino 4 (2 4 5 triflu...

The present invention relates to pharmaceutical composition of fibrate for the method of treatment of renal cell carcinoma. The methods of the present invention can be used in patients with renal cell carcinoma by administering the fibrate preferably bezafibrate, optionally in combination with one or more anti-cance...

There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.

The present invention describes a novel process for preparation of moxifloxacin involving protection of a group prior to reaction and deprotection thereafter to obtain high quality moxifloxacin in higher yields.

An inclusion complexd comprises a substantially pure optical isomer of a benzimidazole compound and cyclodextrin. the complex preferably comprises S-omeprazole and B-cyclodextrin and is made by adding the cyclodextrin to an aqueouse solution of the active material, and then isolating the complex from ther solution. ...

N/A

The present invention discloses processes for synthesis of Gemifloxacin and pharmaceutically acceptable salts, using novel intermediates. The present invention further relates to a besylate salt of Gemifloxacin and the present invention also relates to a process for preparation of a key intermediate (V) or its...

Pharmaceutical inclusion complexes for anti-inflammatory compounds, compositions including the same, and methods of treating employing the complexes and / or compositions are disclosed.

Sildenafil citrate of the formula: 50^- IQCH, is obtained by reacting a compound of the formula: UN ^O N SO- iQw, wherein Rl and R2 are either both H or one is H and the other is methyl with a methylating agent. Dated this 14"" day of September, 2000.

A process for the manufacture of Salbutaamol sulphate, by synthesis of Salbutamol of formula II. by reacting a compound of formula III without isolation of the intermediate stages. (where R1=H, benzyl or substituted benzyl groups R2=HC1-C6 straight or branched alkyl group) with sodium borohydride in presence ...

Abstract The present invention relates to relates to a pharmaceutical composition comprising abiraterone and one or more pharmaceutically acceptable excipients, to a process for preparing such pharmaceutical composition and to the use of the said pharmaceutical composition for the treatment of prostate cancer. ...

A composition comprising rifaximin in the form of particles, wherein substantially all the particles have a particle size less than or equal to 2 micrometres.

The present invention relates to polymorphic forms of palbociclib and processes for preparation thereof, to pharmaceutical compositions comprising palbociclib, and to the use of such compositions for the treatment of cancer.

An improved, liquid laxative formulation comprising the active ingredient selected from the class of anthraquinone glycosides along with at least one polyol is disclosed herein.

Racemic tolterodine free base in crystalline form with improved purity compositions and uses thereof, and processes of preparing the same.

A PROCESS FOR PREPARATION OF PHTHALANES

ABSTRACT PROCESS FOR THE PREPARATION OF POLYMORPHS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR The present invention is directed to Form II, III, IV and V of sertraline hydrochloride and methods for its preparation. According to the present invention, the various polymorphs of sertraline hydrochloride may be produce...

A topical, medicinal spray composition compring of a drug or combination of drugs as solution or suspension in a volatile carrier containing a polymer or combination of polymers which when sprayed on the surface of the skin forms a film on the skin. The components of this invention are not restricted to, but prefera...

A pharmaceutical composition comprises at least one antihistamine at least one corticosteroid and at least one pharmaceutical excipient wherein the at least one antihistamine comprises ebastine or its pharmaceutically acceptable salt solvate ester or physiologically functional derivative thereof and wherein the at l...

Purified citalopram hydrochloride or hydrobromide are made by purifying another different citalopram salt and then converting the purified salt to the hydrochloride or hydrobromide.

Pharmaceutical compositions comprising at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof is disclosed in the present invention. More particularly inhalant compositions containing immunosuppressant for treatment of reversible obstructive re...

A topical, medicinal spray composition comprises of a drug or combination of drug as solution or suspension in a volatile carrier containing a polymer or combination of polymers which when sprayed on the surface of the skin forms a film on the skin. The components of this invention are not restricted to, but prefera...

The present invention relates to a process for the preparation of a neurokinin-1 receptor antagonist. In particular the invention relates to novel key intermediates used in synthesis of Aprepitant and processes for preparation thereof.

ABSTRACT: The present invention relates to pharmaceutical compositions comprising a tyrosine kinase inhibitor, a process for preparing such pharmaceutical compositions and use of the said pharmaceutical compositions for the treatment of cancer more specifically melanoma.

The invention relates to a novel process for the preparation of indazole, compound of formula (I) and to intermediates thereof, the process comprising . (a) reacting indazole compound (V) with dithio-2,2'-bis(N-methylbenzamide compound (IV) in the presence of copper catalyst and a suitable ...

A process for preparing Form A of (S) -5-methoxy-2- [ [ (4-methoxy-3, 5-dimethyl-2-pyridinyl) - methyl] sulf inyl] -1 H-benzimidazole magnesium dihydrate, processes for preparing various intermediates useful in the preparation of Form A of (S) -5-methoxy-2- [ [ (4-methoxy-3, 5-dimethyl-2-pyridinyl) -methyl] sulf iny...

There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A), wherein R" is selected from the group consisting of hydrogen, -C(O)OA, -C(O)CX3, - OH C(O)NH2, -C(O)-NHOH or (a). There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-...

The present invention relates to a novel process for the synthesis of everolimus of formula (I) and intermediates thereof.

The present invention provides a process for the preparation of paliperidone or a pharmaceutically acceptable salt thereof wherein the process comprises condensing a compound of formula (II) with a compound of formula (III) or a salt thereof in a suitable solvent and a base in the presence of a catalyst and an inhib...

The present invention relates to a pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor (NNRTI), and more particularly, relates to a pharmaceutical composition comprising rilpivirine, a process for preparing such pharmaceutical composition, and its use in the treatment of HIV infect...

The present invention relates to a pharmaceutical composition comprising an integrase inhibitor, and more particularly, relates to a pharmaceutical composition comprising dolutegravir, a process for preparing such pharmaceutical composition, and its use in the treatment of HIV infections.

The present invention relates to a multilayer pharmaceutical composition comprising aliphatic amine polymers with one or more pharmaceutical excipients, its method of preparation and use of the said pharmaceutical composition for treatment or prophylaxis of a patient suffering from hyperphosphatemia or chronic kidne...

A pharmaceutical composition comprises a tyrosine kinase inhibitor and one or more pharmaceutically acceptable excipients, a process for preparing such pharmaceutical compositions and use of the said pharmaceutical compositions for the treatment of cancer more specifically advanced or metastatic breast cancer. ...

A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof; (ii) darunavir or a pharmaceutically acceptable salt and ester thereof.

The present invention relates to a pharmaceutical composition comprising a tyrosine kinase inhibitor and one or more pharmaceutically acceptable excipients, a process for preparing such pharmaceutical composition and its use in the treatment of renal cell carcinoma and soft tissue sarcoma.

The present invention relates to an antiretroviral composition comprising immunomodulators and anti-retroviral agents composition for the prevention, treatment or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection.

The present invention provides a pharmaceutical composition comprising lipid microparticles comprising a lipid layer and at least one active pharmaceutical ingredient, wherein the at least one active pharmaceutical ingredient is adsorbed on the lipid microparticle. The present invention also provides a process for p...

Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt ext...

The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.

A topical pharmaceutical composition comprising minoxidil and at least one or more pharmaceutically acceptable excipients

The present invention relates to a parenteral pharmaceutical formulation comprising beta-lactamase inhibitor and beta-lactam antibiotic.

A pharmaceutical composition for inhalation comprising R (+) budesonide and one bronchodilators and optionally one or more pharmaceutically acceptable excipients.

The present invention relates to a compound of formula (A), wherein R is alkyl. Compound A may be used as an intermediate in the preparation of O-desmethyl venlafaxine or a salt thereof, and the present invention provides such a preparation, as well as a process for preparing the compound of formula (A). ...

The present invention relates to a novel process for the preparation of a compound of formula (I) wherein R is a methyl or methoxy group; to certain novel intermediates prepared in such a process and their use.

The invention relates to a valve for an aerosol device. More specifically the invention relates to a valve for an aerosol device for a Metered Dose Inhaler. The valve assembly (60) is receivable in an opening (68) provided in a container (66) of the aerosol device (76) to close said opening (68). The valve assembly ...

The present invention relates to a novel process for the synthesis of polycyclic carbamoyl pyridone derivatives of formula (B): Formula B wherein Ar, W1, W2, W3, X, Y and Z are as defined in the specification; and to novel chemical intermediates for use in such a process.

The present invention provides raloxifene oxalate, including derivatives thereof. In particular, the present invention provides solvates and/or hydrates of raloxifene oxalate, and polymorphs thereof. The present invention also provides processes for preparing the novel compounds, pharmaceutical compositions includin...

A composition comprising rifaximin in the form of particles wherein substantially all the particles have a particle size less than or equal to 2 micrometres.

The present invention relates to a process for the preparation of rufinamide of formula (I), which process comprises: (i) reacting a 2,6-difluorobenzylhaIide of formula (II), wherein X is chloride, bromide or iodide, with an azide to obtain 2-(azidomethyl)-1,3- difluorobenzene of formula (III); (ii) reacting 2-(azid...

The present invention relates to topical pharmaceutical compositions comprising an anti-inflammatory agent in combination with an antibacterial agent, particularly for the treatment of acne.

“DAPAGLIFLOZIN PREMIXES” ABSTRACT: The present invention relates to novel premixes of dapagliflozin, processes for the preparation of such premixes, pharmaceutical compositions comprising the same and their use in medicine.

The present invention relates to a pharmaceutical composition comprising deferasirox a process for preparing such pharmaceutical composition and its use in the treatment of chronic iron overload. The pharmaceutical composition comprises nanosized deferasirox having improved surface area and solubility. It also relat...

Disclosed herein is a process for the preparation of R-(-)-praziquanamine comprising resolving racemic praziquanamine using dextrorotatory isomers of tartaric acid derivatives as a resolving agent. The present invention further discloses an improved process for preparation of R-(-)-praziquantel using R-(-)-praziquan...

The present invention relates to pharmaceutical composition for intranasal or pulmonary delivery wherein the composition comprises an artemisinin derivative and optionally one or more pharmaceutically acceptable excipients. The pharmaceutical composition may be for intranasal delivery may be in the form of a nasal s...

The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. Th...

The present invention discloses process for the preparation of pomalidomide or pharmaceutically acceptable salts thereof and novel solid forms comprising pomalidomide and a coformer. The invention further discloses pharmaceutical compositions comprising the same.

An inhaler device for facilitating the inhalation of a medicament from a pierceable medicament capsule the inhaler device comprising a body (1) having a chamber (14) for receiving a pierceable medicament capsule; piercing means (7) for piercing a medicament capsule received in said chamber (14); and an actuating mem...

The present invention relates to novel crystalline forms of (R)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lH-benzimidazole (Formula 1), to processes for their preparation, to pharmaceutical compositions comprising the same and to the use of such crystalline forms for the treatment of gastr...

The present invention relates to a new crystalline polymorph of brexpiprazole. More specifically, the invention relates to novel Form M of brexpiprazole, process for preparing the novel form of brexpiprazole and pharmaceutical formulations comprising the novel form of brexpiprazole. The present invention also re...

A pharmaceutical composition comprising a beta agonist selected from indacaterol and formoterol in combination with a corticosteroid selected from fluticasone and ciclesonide and optionally one or more pharmaceutically acceptable excipients.

The present invention provides a simple process for the preparation of highly pure intermediate compound 5-formyl-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide through acid-base treatment. The invention further provides use of 5-formyl-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamin...

ABSTRACT- The present invention relates to pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs.

The invention relates to pharmaceutical compositions containing a combination of atazanavir and ritonavir, to methods of making them, and their use in medicine.

The present invention disclosed herein is a low dose pharmaceutical composition comprising deferasirox along with one or more pharmaceutically acceptable excipients. The present invention also disclosed a process for preparation of such low dose pharmaceutical composition and its use in the treatment of chronic iron...

The present invention provides a pharmaceutical competition comprising an antibacterial agent such as Besifloxacin and a steroidal anti-inflammatory agent such as Fiuorometholone, and a method of manufacturing the same. The present invention is particularly useful for treatment of ophthalmic infections associated wi...

Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing rad...

The present invention provides a pharmaceutical solid oral sprinkle composition comprising one or more antiretroviral drugs, and a method of manufacturing the same. The present invention is particularly useful for treatment of an HIV infection, AIDS related complex, or AIDS.

The present invention relates to an environmentally friendly process for preparing rivaroxaban. The present invention provides a process for preparing rivaroxaban of formula I, the process comprising: reacting a compound of formula VI with a base in the presence of a solvent to form a compound of formula VII; and co...

The present invention relates to a pharmaceutical composition comprising voriconazole and an aqueous, non-aqueous, or oily vehicle, or a mixture thereof, and optionally one or more pharmaceutically acceptable excipients; to a process for preparing such a composition, and to the use of such a composition for the prev...

Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or expo...

The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying out the novel process.

Abstract The present invention relates to an efficient process for the separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine and to a process for preparing 9-[(R)-2-[[(R)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]p...

A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure; a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof; and an actuator for actuating discharge of the metered dose to the...

The present invention relates to a pharmaceutical antiretroviral composition comprising (i) a nucleoside reverse-transcriptase inhibitor selected from lamivudine and emtricitabine, (ii) extended release nevirapine, and (iii) tenofovir; a process for preparing such composition and the use of such composition in medic...

“METHOD OF TREATING HYPERTENSION” ABSTRACT Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of cinitapride or derivative thereof. The composit...

The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine festinavir and nevirapine to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses especially acquired immune deficiency...

The present invention provides a process for the preparation of the dextrorotatory isomer of zopiclone (eszopiclone). The present invention also provides eszopiclone di-p-anisolyl-L-tartrate and eszopiclone diacetyl-L-tartrate, which are useful as intermediates in a process for preparing eszopiclone. ...

The present invention provides tiotropium bromide having a low degree of crystallinity. The present invention also provides a complex of tiotropium bromide and polyvinylpyrrolidone, processes for preparing it and pharmaceutical formulations including it.

A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition to as a medicament.

“PROCESS FOR PREPARING AN ENDOTHELIN RECEPTOR ANTAGONIST” ABSTRACT The present invention relates to a process for preparing macitentan of Formula (I): to macitentan prepared according to such a process and to macitentan in substantially pure form.

The present invention relates to novel premixes of Vortioxetine, processes for the preparation of such premixes, pharmaceutical compositions comprising the same and their use in medicine.

The present invention discloses an environmentally friendly and improved process for the preparation of Imatinib and its pharmaceutically acceptable acid addition salts thereof.

A pharmaceutical composition comprising a solid unit dosage form comprising: (i) ritonavir or a pharmaceutically acceptable salt and ester thereof; (ii) darunavir or a pharmaceutically acceptable salt and ester thereof.

The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration) to a process for preparing such a composition and to the use of such a composition for the treatment treatment and/or prevention of respiratory inflammatory or ob...

There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex. ...

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, ...

An inhaler device for inhalation of a medicament from a pierceable capsule comprises a housing for receiving a medicament capsule (10); closure means (3) for closing the housing, said closure means being moveable relative to the housing; piercing means (7) suitable for piercing a medicament capsule; wherein movement...

The present invention relates to a pharmaceutical composition comprising voriconazole and an aqueous non aqueous or oily vehicle or a mixture thereof and optionally one or more pharmaceutically acceptable excipients; to a process for preparing such a composition and to the use of such a composition for the preventio...

Disclosed herein is a pharmaceutical composition comprising crystalline darunavir or its pharmaceutically acceptable solvates, hydrates, esters or salts thereof; process for preparing such pharmaceutical composition and use of the said pharmaceutical composition for the prevention, treatment and prophylaxis of disea...

The present invention provides a pharmaceutical solid oral sprinkle composition comprising one or more antiretroviral drugs and a method of manufacturing the same. The present invention is particularly useful for treatment of an HIV infection AIDS related complex or AIDS.

A pharmaceutical composition comprising carmoterol in combination with a corticosteroid selected from fluticasone, ciclesonide or mometasone, and, optionally, one or more pharmaceutically acceptable excipients.

ABSTRACT: The present invention discloses pharmaceutical compositions for inhalation which comprise one or more bronchodilators and an inhaled corticosteroid. More particularly, the present invention discloses pharmaceutical compositions comprising olodaterol, an inhaled corticosteroid and/or an anticholinergic. Th...

The present invention discloses a pharmaceutical antiretroviral composition comprising at least one or more anti-retroviral agents and to the manufacturing process thereof. Disclosed herein further is the use of said composition for the prevention, treatment or prophylaxis of diseases caused by retroviruses, especia...

There is disclosed crystalline darunavir hydrate substantially free of any non aqueous solvent.

The present invention relates to pharmaceutical compositions for nasal and ocular use, a process for preparing the said compositions.

The present invention relates to long acting dosage forms comprising ulipristal for the treatment and reduction of uterine fibroids.

There is provided a process for the preparation of sitagliptin or a pharmaceutically acceptable salt thereof, and a process for the preparation of intermediate compounds useful in the preparation of sitagliptin. In particular, there is provided a process comprising condensing 3-tert-butoxycarbonylamino-4-(2,4,5-trif...

ABSTRACT: The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs. ...

A nasal spray assembly comprising a nasal device and a container, the container including a reservoir containing a medicament, the reservoir being sealed by a movable piston, the nasal spray assembly being for administering the medicament to the nose of a user, the nasal device comprising a body and a cap, the cap d...

Disclosed herein is a process for preparation of dexlansoprazole sesquihydrate which process comprises contacting 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]-methyl]thio]-lH-benzimidazole with a (+)-diethyl-L-tartrate & titanium isopropoxide in a suitable organic solvent in presence of water, followed by ox...

A pharmaceutical composition comprises a self-emulsifying drug delivery system, wherein the self-emulsifying drug delivery system comprises efavirenz and one or more pharmaceutically acceptable excipients.

Disclosed herein is a pharmaceutical composition comprising zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than l0 mg.

An inhaler device for facilitating the inhalation of a medicament from a pierceable medicament capsule, the inhaler device comprising a body (1) having a chamber (14) for receiving a pierceable medicament capsule; piercing means (7) for piercing a medicament capsule received in said chamber (14); and an actuating me...

There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin.  There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex. ...

The present invention relates to a pharmaceutical antiretro viral composition comprising (i) a nucleoside reverse transcriptase inhibitor selected from lamivudine and emtricitabine (ii) extended release nevirapine and (iii) tenofovir; a process for preparing such composition and the use of such composition in medici...

A novel and improved process for preparation of bortezomib mannitol ester is derived which process avoids excessive use of solvents involves convenient industrially feasible and economical techniques and provides improvements in purity over processes known in the art.

Disclosed herein are stabilized formulations of carfilzomib. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.

The present invention discloses a pharmaceutical composition comprising cinacalcet, a process for preparing such a pharmaceutical composition, and use of the said pharmaceutical composition. The pharmaceutical composition of the present invention specifically discloses liquid and semi-solid compositions of cinacalce...

The present invention provides novel polymorphs of (3S,11aR)-N-[(2,4-difluorophenyl) methyl]-6- hydroxy-3-methyl-5, 7-dioxo-2, 3,5,7, 11, 11a-hexahydro[1, 3]oxazolo[3, 2-a]pyrido[1, 2-d]pyrazine-8-carboxamide including sodium and potassium salts  and pharmaceutical compositions containing these polymorphs . Also pro...

A pharmaceutical composition comprising efavirenz wherein the efavirenz is in the form of nanoparticles.

The present invention relates in general to a topical pharmaceutical composition comprising an antiretroviral agent in combination with a bactericidal agent and an antifungal agent, particularly for use as a contraceptive.

The present invention relates to pharmaceutical compositions comprising an anthelmintic agent. Specifically, the invention relates to a pharmaceutical composition comprising praziquantel or R- praziquantel in nanosized particles and one or more pharmaceutically acceptable excipients. The invention also relates to a ...

“METHOD FOR THE TREATMENT OF CANCERS” ABSTRACT: Methods of treating bladder cancer using adapalene or pharmaceutically acceptable salts thereof in the form of suitable pharmaceutical compositions are disclosed herein. Adapalene can be administered as monotherapy or as part of a comprehensive treatment program...

An improved process for preparing anhydrous tiotropium bromide is disclosed herein.

The present invention discloses a compound having the formula (II): The present invention also discloses a method of preparing a compound of formula (II) comprising condensing a compound of formula (I) with (S,S)-2,8-Diazabicyclo [4.3.0] nonane in an organic solvent to obtain the compound of formula (II). Th...

“STABILIZED LIQUID FOSAPREPITANT FORMULATIONS” ABSTRACT The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration.

The present invention discloses pharmaceutical antiretrovirai compositions comprising at least one reverse transcriptase inhibitor and at least one protease inhibitor in the form of a kit, manufacturing process thereof and use of the said composition for the prevention, treatment and prophylaxis of diseases caused b...

The present invention is directed to novel solid state forms of selexipag, including an amorphous form of selexipag and a selexipag-containing premix, to methods for their preparation, to pharmaceutical compositions comprising them and to their use in medicine, particularly for the treatment of pulmonary arterial hy...

The present invention relates to a process for the preparation of doxazosin or salts thereof.

The present invention provides improved processes for the preparation of Bortezomib, tert-butyl[l-({(lS)-3-rnethyl-l-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano- l,3,2-benzodioxaborol-2-yl]butyl}amino)-l-oxo-3-phenylpropan-2-yI]carbamate of formula (IV) and N-{(lS)-3-methyl-I-[(3aS,4S,6S,7aS)-3a,5,5-tr...

The present invention relates to a topical pharmaceutical composition for use as a contraceptive comprising an antiretroviral agent in combination with a bactericidal agent.

The present invention relates to a dose counter. Particularly but not exclusively the invention relates to a dose counter for use with a Metered Dose Inhaler (MDI). The dose counter comprises a rotary counting element (26) and an actuator (2). The actuator (2) is movable relative to the rotary counting element (26) ...

The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents, the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency synd...

“METHACYCLINE FOR THE TREATMENT OF OVARIAN CANCER” ABSTRACT: Disclosed herein are methods of treating ovarian cancer comprising administering to a subject in need thereof an effective amount of methacycline, or a pharmaceutically acceptable salt thereof. The methacycline can be administered as part of treatme...

“METHOD OF TREATING HYPERTENSION” ABSTRACT: Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of anagrelide or derivative thereof. The composi...

The present invention relates to pharmaceutical compositions comprising polymeric nanoparticles of anticancer drugs.

ABSTRACT The present invention relates to pharmaceutical composition of estrogen receptor modulator for the method of treatment of hepatitis C in humans. The methods of the present invention can be used in patients with hepatitis C administering estrogen receptor modulator preferably Hexestrol, optionally in combin...

The present invention discloses to a hot-melt extruded pharmaceutical composition comprising a calcimimetic drug. The invention also discloses processes for the preparation of the said pharmaceutical composition and its use for the treatment and/or prevention of hyperparathyroidism.

The present invention relates to a hot-melt extruded pharmaceutical composition comprising an antibacterial drug.

The present invention provides a process tor preparing a compound ot" formula (VI) or a salt thereof, the process.comprising: (i) reacting 4-merhoxyphenyl acetone with an amine of formula (VOX) tinder conditions of reductive animation to pro-duce a compound of formula (II) or a salt thereof, wherein there is no isol...

The present invention relates to hot-melt extruded pharmaceutical composition comprising a pharmaceutical active ingredient dispersed as fine particles in a water soluble or insoluble polymer or a combination of both the polymers and a method of preparation thereof.

An inhaler device (2) is for the inhalation of particulate substances is provided. The device comprises a housing (5) having first and second openings, a first air passageway (11) being defined through said housing between said first and second openings, an extraction member (40) extending from said housing and havi...

A pharmaceutical composition comprising rifaximin in the form of a suppository dosage form.

A solid oral pharmaceutical composition comprises greater than 100 mg of imatinib, and one or more pharmaceutically acceptable excipients. A process for preparing a pharmaceutical composition comprising than greater than 100 mg of imatinib, and one or more pharmaceutically acceptable excipients comprises manufacturi...

A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.

A pharmaceutical combination comprising lamivudine, or a pharmaceutically acceptable derivative thereof; stavudine, or a pharmaceutically acceptable derivative thereof; and efavirenz, or a pharmaceutically acceptable derivative thereof; for simultaneous, separate or sequential use in the treatment or prevention of v...

Crystalline sertraline free base is made by treating a sertraline salt with a base and recovering the sertraline base in crystalline form.

The present invention provides an antiretroviral solid oral composition comprising one or more antiretroviral drugs, for example protease inhibitors such as lopinavir, ritonavir or a combination thereof with one or more excipients. The invention provides a composition which is smaller for a given amount of said acti...

The present invention provides dexrabeprazole magnesium hydrate and a process for its preparation. The present invention also provides a magnesium, calcium or potassium salt of dexrabeprazole, optionally in amorphous form, and processes for its preparation.

CRYSTALLINE POLYMORPH OF ESOMERAZOLE POTASSIUM AND PROCESS FOR PREPARATION THEREOF

The invention discloses new compounds of formula (III): wherein R is a C1-4 liner or branched alkyl group. The invention also discloses new compounds of formula (IV) where M is a metal. The invention further discloses methods of making compounds of formulas (III) and (IV) and methods of making donepezil and pharmace...

N/A

The present invention relates to an amorphous form of 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide or its pharmaceutically acceptable salt, processes for preparation of amorphous form and compositions comprising the same.

The present invention relates to an inhaler device and provides such a device comprising first and second compartments (4, 6) movable relative to one another such that, upon movement of said components (4, 6), operating means (16, 28, 40, 42, 44, 46) advances a cartridge compartment (140) into a predetermined positi...

A pharmaceutical product comprising (i) at least one B-2 adrenoreceptor agonist, and (ii) at least one antihistamine, as a combined preparation, for simultaneous, separate or sequential use in the treatment of respiratory diseases

The present invention discloses multi-dose inhalers and more particularly inhalers which are used with piercable sealed cartridge having a plurality of medicament compartments. Such inhalers allow for the administration of predetermined doses of medicament (typically a dry powder medicament).

A pharmaceutical composition in a dosage form suitable for inhalation comprises a therapeutically isomer of a betamimetic agent or a salt, solvate, ester, derivative or polymorph thereof substantially free of the less therapeutically effective isomer(s) of said agent and an anti-cholinergic agent or a salt, solvate,...

A novel crystalline form of irinotecan hydrochloride designated herein Form I, which is charasterized by X-ray powder diffraction pattern having the peaks at [theta] values at about 5.26; 8.56; 1.46; 15.28; 17.32; and 24.70+-0.2 Angstroms. The polymorphic form I is having higher solubility at temperature of 25-30(0)...

N/A

Disclosed herein are novel crystalline solvates of Dasatinib selected from hem i-ethanolate form of Dasatinib, designated as `Form I", novel tetrahydrofuran solvates of Dasatinib, designated as `Form II", novel acetonate of Dasatinib, designated as `Form III"; and processes for preparation thereof. ...

Disclosed herein is a pharmaceutical position comprises tibolone, a water-soluble starch and optionally a pharmaceutically acceptable carrier. Preferred compositions comprise an inclusion complex of tibolone and a water-soluble starch, in particular cyclodextrin. The present invention further discloses process of ma...

Disclosed herein is an improved process for the synthesis and purification of antimalarial drug Lumefantrine involving Grignard reaction.The process comprises condensation of 2,7-dihloro-9H-fluorene-4-oxiran with p-chloro benzaldehyde to yield 2,7-dichloro -9(4-chloro benzylidine) fluorine-4-oxirane; reaction of 2,7...

The invention relates to processes for making montelukast of formula I and to intermediates for use in the process, in particular compounds of formulas 2 - 7:

Disclosed herein is a process of preparing imatinib, either as the free base or as an acid addition salt, which comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (IIa) with a 4-(4-methyl-piperazino methyl)benzoic acid of formula (IIIa) using a coupling agent in the presence of ...

A process for the preparation of valganciclovir with triacetyl ganciclovir (V) as a starting material, comprising the following steps,: selected hydrolysis, reacting with a coupling agent and a solvent, followed by hydrolysis under basic conditions and hydrogenolysis in the presence of a catalyst. ...

The present invention discloses a process for preparation of 4-[1-(4-cyano phenyl)-1-(1,2,4-triazol-1-yl) methyl] benzonitrile, substantially free from its isomeric impurity.

The present invention relates to processes for the preparation of rosiglitazone, rosiglitazone prepared thereby and pharmaceutical compositions and therapeutic uses thereof, and methods of treatment employing the same.

Anhydrous crystalline fexofenadine hydrochloride From C, crystalline fexofenadine acetate monohydrate From D, crystalline fexofenadine acetate dehydrate From E and Crystalline fexofenadine free base monohydrate From F processes of preparing the same pharmaceutical compositions thereof, therapeutic uses thereof and ...

There is provided a novel pharmaceutical composition for topical administration comprising one or more antimycotics (ciclopirox) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptabl...

The present invention is concerned with a process for the preparation of 2n-butyl-4-spirocyclopentane-l-[(2'-(te, a-zol-5-yl)biphenyl-4-yl) methyl]-2-imidazolin-5-one hydrochloride, irbesartan hydrochloride, novel hydrated and anhydrous crystalline forms thereof, amorphous irbesartan hydrochloride, formulations cont...

A process for the preparation of compounds of formula (IA), where R=CH3 (i.e. temozolomide) comprising diazotizing a compound of the formula (IIA) where in R is as defined above in the presence of at least one metal halide, an acid and a source of nitrous acid, followed by conversion of acidic solution containing te...

N/A

The present invention discloses a nutritional supplement comprising green tea extract along with atleast one methylating agent and atleast one anti-oxidant or their pharmaceutically available salts, solvates, derivatives or enantiomers thereof in a pharmaceutically acceptable carrier. The invention further discloses...

1. A method of making 2, 6-diamino-4, 5, 6, 7-tetrahydro-benzothiazole, which method comprises the steps in sequence of, (i) reacting bromine with a solution of 4-acetamido-cyclohexanone in water to produce 2-bromo-4-acetamido-cyclohexanone; (ii) adding thiourea to produce 6-acetylamino-2-amino-4, 5, 6, 7-tetrahydro...

The present invention relates to Disclosed herein a process for synthesis of 9a-fluoro-11B,21-dihydroxy-16a, 17a-isopropylidenedioxy-1,4-pregnadiene-3,20-dione (I) which comprises; treating 9B,11B-epoxy-16a,17a,21-triol-pregna-1,4-diene-3,20-dione-21-acetate of formula (II), with acetone and hydrogen fluoride. ...

A process for the preparation of trityl olmesartan comprising (a) condensing 4- (1-hydroxy- 1-methylethyl) -2-propyl-imidazol-5-carboxylic acid alkyl ester with trityl biphenyl bromide in the presence of a polar aprotic solvent and a base selected from the group consisting of alkali metal carbonates, alkali metal hy...

N/A

A polymorh of alfuzosin hydrochloride and a process for its preparation is described. The polymorph has significant enhancement in bioavailability and tablets made therefrom have better hardness and improved disintegration time.

N/A

A process for the preparation of anastrozole which comprises: a) brominating 3,5-bis(2-cyanoprop-2-yl)toluene (II) in an organic solvent using a brominating agent to obtain 3,5- bis(2-cyanoprop-2-yl)benzylbromide (III); b) heating the reaction mass of step a) to the reflux temperature of the organic solvent for a pe...

There is provided an oral formulation which includes an intragranular phase comprising a bisphosphonic acid derivative and at least one carbohydrate alcohol, together with an aqueous binder. There is also provide a process of preparing the same and a therapeutic method employing such a formulation in the treatment o...

A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier.

A pharmaceutically acceptable oral formulation comprising core material which comprises a therapeutically effective amount of a 5-HT-receptor agonist, or a pharmaceutically acceptable salt, solvate or derivative thereof, which core material is provided with a substantially water resistant coating comprising one or m...

A pharmaceutical paste formulation for oral administration, which comprises a proton pump inhibitor, or a pharmaceutically acceptable salt, derivative or enantiomer thereof, and an oily vehicle.

Disclosed herein is pharmaceutical dosage form comprising matrix of atleast one corticosteroid/s and atleast one polymer optionally with one or more pharmaceutically acceptable excipients; in particular multi-unit oral pharmaceutical dosage forms and process for making the same.

Disclosed herein is process for preparation of montelukast and its alkali and alkaline earth metal salts. The present invention also discloses the inter conversions of the said salts of montelukast.

The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a powder XRD pattern with peaks at 10.8,11.9, 13.0, 18.3,28.5 ± 0.2 degrees 2 theta. Crystalline levosalbutamol sulphate Form ...

A PROCESS FOR SYNTHESIS OF MONTELUKAST SODIUM

Disclosed herein as an aerosol composition comprising a therapeutically effective amount of troventol either alone or in combination with one or more suitable therapeutic agents formulated together with one or more pharmaceutically acceptable carriers suitable for use in the treatment of bronchospasms and related di...

The present invention is concerned with a novel formulation comprising calcitonin, a process for preparing such a formulation, therapeutic uses thereof and methods of treatment, employing the same. More particularly, there is provided a pharmaceutical formulation for nasal administration, which formulation comprises...

A patch, or patch forming composition, comprising at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a pharmaceutically acceptable carrier or excipient therefore, formulated for delivery of said least one immunosuppressant, o...

The present invention is concerned with the use of of at least one immunosuppressant,or a pharmaceutilcally acceptable salt, solvate orphysiology functional derivate thereof,in the treatment of topical immune disorders of the scalp,and scalp condition, and compositions suitable for such use. ...

A process of preparing imatinib, either as the free base or as an acid addition salt, which process comprises reacting N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidine amine of formula (II) with a 4-(4-methyl-piperazino methyl)benzoyl halide of formula (III) in the presence of an inert organic solvent, so as to ...

A pharmaceutical composition comprising 10-120 mg lamivudine, 1-30 mg stavudine and 50-170 mg nevirapine for paediatric treatment of viral infections is disclosed. One particularly prepared composition comprises a tablet containing 12 mg stavudine, 60mg lamivudine and 100mg nevirapine. Another particularly preferred...

The present invention relates to an improved process for the synthesis of Ibandronate sodium of formula (I). The present invention also provides novel processes for the synthesis of 3-[N- (methylpentyl) amino] propionic acid (III).

Disclosed herein is a novel crystalline polymorphic Form-A of Topotecan hydrochloride which is characterized by an XRD pattern having peak positions at 6.08, 6.94, 8.10, 9.96, 10.16, 11.68, 12.28, 13.08, 13.62, 14.32, 15.44, 16.46, 16.56, 17.58, 18.42, 19.32; 20.14, 21.22, 22.54, 22.72, 23.38, 24.14, 24.36, 24.78, 2...

The invention relates to a process for the preparation of anagrelide, and for the preparation of intermediates for use in preparing anagrelide. The invention also relates to the inteπnediates per se, in particular compounds of formula (V) where R constitutes a suitable leaving group, which may not be hydrogen. The R...

Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG 5 CoA reductase inhibitors in combination with cholestrol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt ex...

In an embodiment, the present invention provides a process for preparing (-)-6-(4-aminophenyl)-5-methylpyridazin-3-(2H)-one, which process comprises: a) reacting racemic 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3-(2H)-pyridazinone of formula II with a chiral tartaric acid derivative to obtain a diastereomeric salt of ...

Sibutramine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethyl-amine, free base in crystalline form, compositions containing the same and uses thereof.

The present invention discloses for the preparation of boterzomib via intermediate. A and various other intermediates. Also disclosed herein is the preparation of bortezomib, optionally in one pot, from L-phenyl alanine, comprising of reacting L-phenyl alanine with triphosgene in presence of disodium hydrogen phosph...

Disclosed herein a process of highlighting the engravements on a tablet comprising: (a) spraying onto said tablets a coating composition comprising a coating material and a solvent, (b) spraying the said tablets with a second coating composition comprising a filling material and a solvent or spraying onto the said t...

Clopidogrel, or a pharmaceutically acceptable salt thereof in an amorphous form.

The present invention discloses an improved and cost-effective process for preparation of lercanidipine hydrochloride with good yield and high purity.

A pharmaceutical combination comprising (a) a combination of two or more bronchodilators; or (b) a combination of at least one bronchodilator in combination with at least one corticosteroid.

Transdermal spray formulations containing a pharmaceutically active agent and methods for administering the same are proMided. The formulations comprise the pharmaceutically active agent, a VP/VA copolymer and a non-aqueous vehicle. The formulations fUrther comprise an anti-nucleating agent to prevent recrystallizat...

Disclosed herein is a process for preparation of Anastrazole with purity greater than 99.8%, which comprises alkylation of purified 3,5-bis(2-cyanoprop-2-yl)benzylbromide with 1, 2,4 triazole, followed by isolation and purification of Anastrazole using environmental friendly solvents.

The present invention provides a stable aerosol formulation comprising bronchodilatory medicament or its salts, solvates, tautomers, derivaties, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof. A preferred composition comprises beta-agonist and anticholinergic agent. Methods of making the composition ...

A process for the preparation of a salt of N-(3-ethynylphenyl)-6,7-bis(2- methoxyethoxy)quinazofin-4-amine comprising reacting a 4-haio-6,7-bis(2-methoxyethoxy) 5 quinazoiine with 3-aminophenyi acetylene or an acid salt thereof under acidic conditions to form the corresponding acid salt of N-(3-ethynyiphenyl)-6,7-...

There is provided a compound of formula (III), and a process for preparing a compound of formula (V) comprising converting a compound of formula (III) to the compound (V), wherein (X) is fluoro, chloro, bromo or iodo. There is also provided a process for preparing a compound of formula (Xl) comprising converting a c...

Racemic tolterodine free base in crystalline form, tolterodine with improved purity, compositions and uses thereof, and processes of preparing the same

The present invention is concerned with duloxetine free base in crystalline form, and also novel polymorphic forms thereof.

A process of preparing rosiglitazone, or a pharmaceutically acceptable salt thereof, which process employs an intermediate metabisulphite complex of 4-[2-(N-methyl-N-(2-pyridyl)amino) ethoxy] benzaldehyde, which metabisulphite complex is represented by following formula (III); where X represents an alkali metal. The...

This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions compris...

The present invention relates to a process for the preparation of 4-[1-(4-cyano phenyl)-1- (1 ,2,4-triazol-1-yl) methyl] benzonitrile (letrozole), substantially free from its isomeric impurity. The preparation involves reaction of 4-[1-(1 H-1 ,2,4-triazol-1-yl)methylene benzonitrile with 4-fluorobenzonitrile in the ...

The invention relates to an aerosol device. More specifically the invention relates to an aerosol device for a Metered Dose Inhaler. The aerosol device (76,176) comprises a container (66,166) with an opening at one end, a self sealing valve assembly (60,160) supported within the container (66,166), and a cap member ...

An N-[(2"-(l-triphenyI methyl tetrazole-5-yl)bipheny!]-4-yI] methyl]-L-valine benzyl ester organic salt of formula (TVA) wherein A represents an organic carboxylic acid, a process for its preparation and its use in the synthesis of valsartan or salts thereof.

The present invention relates to processes for the preparation of rosiglitazone, rosiglitazone prepared thereby and pharmaceutical compositions and therapeutic uses thereof, and methods of treatment employing the same.

Sibutramine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethyl-amine, free base in crystalline form, compositions containing the same and uses thereof.

The invention relates to an aerosol device. More specifically, the invention relates to an aerosol device for a Metered Dose Inhaler. The aerosol device (76,176) comprises a container (66,166) formed at least in part from transparent or translucent material. The amount of a substance in the container (66,166) is the...

A inhaler for an inhalation formulation, comprising a canister containing a pharmaceutical composition under pressure; a metering valve for measuring a metered dose of the composition from the canister for administration to a patient in need thereof; and an actuator for actuating discharge of the metered dose to the...

A PROCESS OF PREPARING IMATINIB

A Pharmaceutically acceptable alendronate salts in an amorphous from.

A pharmaceutical dispensing aid (10) comprising a transparent canister (12) made of polycarbonate polymer. The canister (12) is configured to contain a formulation (14) comprising one or more active pharmaceutical ingredients, a propellant or a mixture of propellants along with any other pharmaceutically acceptable ...

The present invention relates to a pharmaceutical lozenge composition comprising desloratadine its method of preparation and use in preventing or treating the allergenic reactions or other histamine induced disorders.

N/A

The present invention relates to an improved process for the synthesis of Ibandronate sodium of formula (I). The present invention also provides novel processes for the synthesis of 3-[N- (methylpentyl) amino] propionic acid (III).

One-pot process for the preparation of nateglinide, which process comprises reacting an alkyl ester of D-phenylalanine of formula (II) where R represents C₁-4alkyl, typically methyl, either as the free base or in salt from (typically the hydrochloride), with trans-4-isopropylcyclohexanecarboxylic acid of formula (II...

A pharmaceutical formulation comprising (i) a sustained release layer comprising at least one xanthine, and (ii) an immediate release layer comprising at least one β-2 adrenoreceptor agonist selected from the group consisting of long acting and short acting; β-2 adrenoreceptor agonists.

An inhaler (1) device for inhalation of a medicament from a pierceable capsule (10) comprises a housing (2) for receiving a medicament, capsule, closure means (3) for closing the housing, said closure means being moveable relative to the housing; piercing means (7) suitable for piercing a medicament capsule; wherein...

A pharmaceutical aerosol formulation comprising an active material coated with a polymer, in combination with a propellant, optionally with other pharmaceutically acceptable excipients.

A pharmaceutical composition comprising at least on therapeutically selective isomer of a B-2-adrenergic agonist. or a salt, solvate, physiologically functional derivative or prodrug thereof, and at least one therapeutically selective isomer of an H1-receptor antagonist, or a salt, solvate, physiologically functiona...

This invention disclosed pharmaceutical formulation for the treatment of human immunodeficiency virus (HIV) infection. In particular, the invention discloses pharmaceutical formulation comprising a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor and to pharmaceutical produ...

Disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of mirtazapine or its salts or enantiomers or derivatives or solvate thereof, alone or in combination with another active ingredient, wherein mirtazapine is complexed with an ion - exchange resin to mask the bitter taste o...

A stable pharmaceutical composition comprises desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol. Preferred compositions comprise, in addition to desloratadine, from 50 to 80% polyol, from 5 to 15% disintegr...

Disclosed herein is a simple, one-pot process for the preparation of fluticasone propionate comprising treating the compound of formula II with piperdine to obtain compound of formula III, which is reacted in situ with bromo fluoro methane in the absence of any inorganic base to yield a compound of formula (I). The ...

There is provided a process for preparing febuxostat of formula (I) or a pharmaceutically acceptable salt thereof, the process comprising: condensing a compound of formula A with a compound of formula B to form an ester of febuxostat; hydrolyzing the ester of febuxostat to febuxostat, and optionally converting the f...

A pharmaceutical composition comprising a combination of Withania somnifera extract with at least one anti-retrovira! agent and one or more optional pharmaceutically acceptable excipients.

The present invention is to provide a novel process for preparing pregabalin. There is provided a process via new intermediates for the synthesis of pregabalin.

In the present invention, there is provided a transdermal spray formulation wherein the said transdermal spray formulation comprises (i) a pharmaceutically active agent, (ii) VP/VA copolymer and (iii) a volatile solvent or nonvolatile solvent or a combination thereof.

The invention provides a convenient oral pharmaceutical formulation comprising one or more pharmaceutical active ingredient selected from H2 receptor antagonists, antibiotics, analgesics, cardiovascular agents, peptides or proteins, hormones, anti-migraine agents, anti-coagulant agents, anti-emetic agents, anti-hype...

Improved process for the synthesis of ciclesonide and its crystal form.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

There is provided a stable pharmaceutical composition comprising a plurality of coated leukotriene antagonist or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs or pha...

An aerosol composition suitable for use in the treatment of bronchospasms and related disorders comprises a therapeutically effective amount of troventol either alone or in combination with one or more suitable therapeutic agents and one or more pharmaceutically acceptable carriers. The composition preferably contai...

Crystalline raloxifene hydrochloride in hydrated form, particularly the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and uses thereof.

A new polymorph of moxifloxacin hydrochloride is described, together with a method for making the polymorph. In addition, new intermediates in the formation of moxifloxacin hydrochloride are described, having formulas (I) and (II).

The invention relates to an aerosol device. More specifically the invention relates to an aerosol device for a Metered Dose Inhaler. The aerosol device (76,176) comprises a container (66,166) with an opening at one end, a self sealing valve assembly (60,160) supported within the container (66,166), and a cap member ...

A pharmaceutical formulation comprising an anti-obesity agent, such as sibutramine, and at least one acidulant, such as fumaric acid, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

The present invention relates to a pharmaceutical formulation that is a solid dosage form comprising an immunosuppressant drug, namely sirolimus. There is also provided a process of preparing a formulation as provided by the present invention and the use thereof in the treatment and / or prevention of disorders or c...

Disclosed herein is a simple and efficient process for the synthesis of lercanidipine hydrochloride, wherein 1,1 ,N-trimethyl-N-(3,3 -diphenylpropyl)-2-aminoethylacetoacetate and 2-(3-Nitrobenzylidene)-3-oxo-butyric acid methyl ester are subjected to a simple Michael addition under mild reaction conditions to obtain...

The present invention discloses pharmaceutical compositions comprising a therapeutically effective isomer of a betamimetic agent for the treatment of bronchoconstriction, asthma and related disorders thereof.

The present invention provides an inhaler device (1) for dispensing multiple doses of medicament, the inhaler comprising medicament extraction facilitating means (22) for locating adjacent or in a compartment (42) of a received medicament cartridge and thereby allowing an extraction of medicament from the compartmen...

Transdermal spray formulations containing a pharmaceutically active agent and methods for administering the same are provided. The formulations comprise the pharmaceutically active agent, a VP/VA copolymer and a non-aqueous vehicle. The formulations further comprise an anti-nucleating agent to prevent recrystallizia...

A process for preparing (+)duloxetine, or an acid addition salt thereof, which process comprises resolving racemic (±)duloxetine with a chiral acid so as to obtain a salt of the chiral acid and (+)duloxetine, substantially free of (-)duloxetine; and (ii) if desired, converting the salt prepared in step (i) to the fr...

Disclosed herein is anti-malarial parmaceutical composition comprising artesunate and lumefantrine in therapeutically effective amounts provided as single dosage unit. The invention also discloses a method of making the pharmaceutical composition, and to the use of the composition in the treatment of malaria. ...

A process for preparing of trandolapril comprising the steps of reacting sub-molar proportion of N- [1-(S)-ethoxy carbonyl-3- phenyl propyl ]-L-alanine N- carboxyanhydride with trans-octahyrdro-1H-indole-2-carboxylic acid and optionally with (2S,3aR,7aS) octahydro-1H-indole-2-carboxylic acid, in the presence of orga...

Disclosed herein an inhaler device comprising means for receiving a container of medicament, and a chamber having an outlet through which medicament dispensed from said container is inhaled during use of the inhaler device; wherein said chamber comprises a first inlet means through which medicament dispensed from sa...

A pharmaceutical combination comprising lamivudine, or a pharmaceutically acceptable derivative thereof; zidovudine, or a pharmaceutically acceptable derivative thereof; and efavirenz, or a pharmaceutically acceptable derivative thereof; for simultaneous, separate or sequential use in the treatment or prevention of ...

A pharmaceutical combination comprising lamivudine, or a pharmaceutically acceptable derivative thereeof; stavudine , or a pharmeceutically acceptable derivative thereof; and efavirenz or a pharmaceutically acceptable derivative thereof; for simultaneous,separate or sequential use in the treatment of prevention of v...

There is provided a process for preparing dorzolamide and processes for preparing intermediates useful in the preparation of dorzolamide. In particular, there is provided a process for preparing an acetoamido sulfone of formula (viii) comprising oxidation of a hydroxysulfonamide of formula (vii) in the presence of a...

The present invention provides a novel process for the preparation of a compound of formula (III), and novel processes for preparing escitalopram using the compound of formula (III).

A metered dose inhalation formulation for once daily administration comprises salmeterol, or a physiologically acceptable salt thereof; and a propellant. A dry powder inhalation formulation for once daily administration comprises salmeterol or a physiologically acceptable salt thereof and a diluent. Also provided is...

A process for the preparation of crystalline Zopiclone comprising i) suspending zopiclone in a mixture of acetonitrile and diisopropyl ether, filtering and drying the resulting solid; ii) dissolving the solid in step i) in N,N-dimethylformamide to get a clear solution; iii) heating and then precipitating solid; iv) ...

The invention relates to a pharmaceutical composition comprising liposomes and and at least one pharmaceutically acceptable excipient, wherein the liposomes comprise a lipid core containing voriconazole. The invention also relates to a method of making pharmaceutical compositions and to their use as a medicament. ...

The present invention provides a stable topical foam preparation comprising a steroid or its salts, solvates, tautomers, drivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof and a keratolytic agent or its salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polym...

An improved process for the preparation of telmisartan, or a pharmaceutically acceptable salt thereof, comprises subjecting 1H-Benzimidazole-2-n-propyl-4-methyl-6-(1'-methyl benimidazole-2'yl) of formula (II) and methyl-4-(bromomethyl) biphenyl-2-carboxylate of formula (III) to condensation and hydrolysis in a singl...

A pharmaceutical aerosol formulation comprising an active material coated with a polymer, in combination with a propellant, optionally with other pharmaceutically acceptable excipients.

The present invention relates to apparatus for administering medicament and particularly, but not exclusively to apparatus for administering powdered or volatile composition by oral or nasal inhalation. The invention provides a device (2) comprising a body (4, 6) defining a chamber (48) for receiving composition to ...

Title : " PERINDOPRIL" A Pharmaceutically acceptable salt of perindopril of formula (I) is made from a protected precursor compound of formula (II) wherein R represents a carboxyl protecting group, which process comprises subjecting a compound of formula (II) to deprotection of the carboxylic group COOR attached ...

The present invention relates to a topical mousse composition for administration of mometasone, method of manufacturing the said topical composition and its use in the treatment and/or prevention of skin diseases.

A topical foam composition comprising one or more corticosteroids or their salts, solvates, prodrugs, , solvates, derivatives, esters, polymorphs or enantiomers thereof; a quick-break foaming agent, a propellant and Hydrochloric acid and other suitable pharmaceutically acceptable excipients. The invention further di...

The present invention provides a process for preparing donepezii or a salt thereof the process comprising reducing a l-benzyl-4-[(5,6-diemexy-l-indanon-2-yl)methyiene]pyridonium halide of formula (II), wherein X is bromide or chloride, in the presence of an ionic compound, a solvent, a catalyst and a source of hydro...

N/A

N/A

The present incention disclosed stable pharmaceutical formation comprising at least one active ingredient selected from the class of benzimidazoles along with suitable pahramceutically acceptable excipients thereof eherein the solvent use for coating the said formulation is water.

N/A

process for preparing alfuzosin or a salt thereof comprising: (a) condensing 4-amino-2- chloro-6,7-dimethoxyquinazoline with 3-methylaminopropionitrile in the presence of a polar aprotic solvent selected from the group consisting of diglyme, dimethyl formamide, t- butanol, hexamethylphosphoramide or mixtures thereof...

Disclosed herein is pharmaceutical formulation in a solid dosage form which comprises of an antipsychotic drug.

An improved pharmaceutical composition comprising at least one long acting (b-2 adrenoreceptor agonist, at least one short acting anti-cholinergic agent, and at least one further anti-inflammatory agent, as a combined preparation for simultaneous or sequential use in the treatment of respiratory diseases. ...

A pharmaceutical composition comprising efavirenz wherein the efavirenz is in the form of nanoparticles.

An inhaler device for inhalation of a medicament from a pierceable capsule comprises a housing for receiving a medicament capsule; closure means for closing the housing, said closure means being moveable relative to the housing; piercing means suitable for piercing a medicament capsule; wherein movement of the closu...

Amlodipine mesylate monohydrate is prepared either from anhydrous amlodipine mesylate, or in the presence of a water immiscible solvent medium from amlodipine free base and methane sulphonic acid.

A process for preparing a compound of formula (V) or its enantiomer, which comprises: (a) reacting racemic aminoindan of formula (II) or its enantiomer with allylhalide in presence of a base and an organic solvent at a temperature ranging from 25 C to the reflux temperature of the solvent to give compound of formula...

The present invention relates to a novel pharmaceutical composition comprising of antiretroviral drugs suitable for administration in children.

A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior, art combination therapies. The invention also provides a...

The invention relates to a pharmaceutical composition comprising a core containing a HMG- CoA reductase inhibitor, and a film coating surrounding the core. In an embodiment, the core is substantially devoid of any binder, diluent or filler, which allows the composition to be made in relatively small size (eg unit do...

The present invention relates to alkaline earth metal salts of bosentan, anhydrous bosentan, polymorphic forms thereof, amorphous bosentan and processes for preparing them. The present invention further relates to a process for the preparation of bosentan and its pharmaceutically acceptable salts. ...

The present invention relates to an aerosol device and more specifically, but not exclusively, to an aerosol device for a Metered Dose Inhaler. According to a first aspect of the present invention there is provided an aerosol device comprising a container and a valve arrangement, the container receiving the valve a...

A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients.

N/A

Disclosed herein is a pharmaceutical composition comprising, a core comprising an antianginal agent, an osmotic agent, and, optionally, one or more pharmaceutically acceptable excipients; and a semipermeable membrane surrounding the core, wherein the semipermeable membrane includes at least one aperture therein thro...

Invention relates to a pharmaceutical composition comprising i) a core consisting of a non-steroidal anti-inflammatory drug(NSAID) or its pharmaceutically accepted salts, solvates, tautomers, derivatives, enantiomers,isomers,hydrates, prodrugs or polymorphs and one or more pharmaceutically acceptable exciepients wh...

Disclosed herein is a pharmaceutical composition of one or more actives comprising i) atleast one blood pressure lowering agent or its salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs; and ii) at least one lipid regulating agent or its salts, solvates, tautomers, deriva...

An oral pharmaceutical formulation comprisiag an active ingredient in combination with one or more pharmaceutical adjuvants, wherein the active ingredient, or combination of the active ingredient and the or each adjuvant, is coated with water soluble polymer or combination of n water soluble and a water insoluble po...

(57) A transdermal pharmaceutical composition for spraying comprising: a. pharmaceutically active agent, b. at least one penetration enhancing agents, comprising a phospholipid, a lipid or a combination threr of ", c. film forming polymer, such as a copolymer of polyvinyl alcohol and polyvinyIpyrrolidone d.vchicle ...

A process for preparing (+)duloxetine, or an acid addition salt thereof, which process comprises resolving racemic (±)duloxetine with a chiral acid so as to obtain a salt of the chiral acid and (+)duloxetine, substantially free of (-)duloxetine; and (ii) if desired, converting the salt prepared in step (i) to the fr...

A topical foam pharmaceutical composition for rectal administration comprising rifaximin in the form of nanosized particles is described. Also described is a method of making the composition and the use of the composition to as a medicament.

The invention relates to a pharmaceutical composition containing as active ingredients Sildenfil or a suitable physiologically accepted salt thereof in particular a composition for intra nasal administration, comprises a suspension or a solution of a suitable pysolocially acceptable salt or solvate thereof as active...

A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient.

The present invention relates to a topical formulation comprising one or more anti-infectives or its pharmaceutically acceptable salts, silver compounds like nano silver particles and other pharmaceutically acceptable excipients for prophylaxis and/or treatment of associated infections and a method of manufacturing ...

The present invention discloses a pharmaceutical composition comprising a solid unit dosage form, comprising of. (i) a protease inhibitor, or a pharmaceutically acceptable salt thereof and (ii)a cytocltrome P450 inhibitor. or a pharmaceutically acceptable salt thereof; wherein, said protease inhibitor is preferabl...

Invention provides three new polymorphic from of Olanzapine for treatment of psychotic conditions. The new polymorphic forms of Olanzapine are designated as form III form IV and form V, which are conveniently prepared by dissolving Olanzapine in an aqueous organic or inorganic acid and precipitated using a suitable...

A antimycotic composition comprising Terbibafine as an active agent in the from of an acidic-additive salt, a thickener, a solubilizer and target additives.

A pharmaceutical composition for topical application in the form of a medicated stick which comprises an active ingredient; 10 to 90% by weight of a solvent comprising one or more polyphydric alcohols; 0.5 to 5% by weight of dibenzylidene sorbitol; 0.5 to 1 % by weight of a thickening agent comprising one or more ch...

A method/process for the manufacture of a pharmaceutical composition for topical administration in the form of a medicated stick which comprises an active ingredient; 10 to 90% by weight of solvent comprising one or more polyhydric alcohols; 0.5 to 5% by weight of dibenzylidene sorbitol; 0.5 to 1% by weight of a thi...

A composition for controlling asthma, which comprises of R-salbutamol sulphate equivalent, orally administered liquid, dry powder inhalers, aerosols, nebuliser solutions and ophthalmic solution, wherein the tablets can be sustained release or in combination with drugs, and the liquid can also in combination with oth...

A topical medicinal aerosol compositions and preparations thereof as sprays, especially wherein the topical medicament is drug which may be anti-emetic, anti-anginal, anti-inflammatory, steroid or hormonal steroid.

Crystalline Form C of tenofovir disoproxil, salts thereof and a process for its preparation. The process involves adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water, whereby the crystalline Form C of tenofovir disoproxil precipitates. The crystalline Form C of tenofovir ...

The pharmaceutical composition in the form of a stable oil-in-water microemulsion prepared in accordance process of the invention consists essentially of water-insoluble pharmaceutically active material; C8 to C20 propylene glycol esters of fatty acids of vegetable oils and glyceryl esters of fatty acids or fatty ac...

A antimycotic composition and a process of preparation thereof, comprises of terbinafine compound (I), as the active agent in the form of an acidic salt. Viscosity imparting agent, emollients and additives in the composition comprises water, lower glycol, non-ionic surfactant, and representing an emulsion of "oil-in...

A method of preparation a formulation in the form of dry powder such formulation essentially free of absorption enhancers and capable of encapsulated in a capsule body or the like construction for administration by inhalation comprising forming a primary ingredient comprising insulin or its analogue, such as, insuli...

An improved process for preparation of Proton Pump Inhibitors is disclosed. Disclosed method is an improved process for producing Proton Pump Inhibitors employing a preferred oxidizing agent at controlled temperature involving a simple, economic, one-step, eco-friendly and green chemistry process. ...

The present invention describes a pharmaceutical composition for topical immunotherapy of scalp and scalp conditions. More specifically, the invention discloses a composition comprising immunosuppressants in a pharmaceutically acceptable formulation, precisely suitable hair adornment composition such as hair-mousse....

A patch, or patch forming composition, comprising at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a pharmaceutically acceptable carrier or excipient therefor, formulated for delivery of said least one immunosuppressant, o...

A spacer device for the oral administration of a volatile medium containing a medicament comprises a chamber (110) having an inlet (102) to admit a measured dose of medicament and an outlet (104) to be received in the mouth, wherein the spacer comprises a butterfly valve (106). Preferably, the chamber comprises two ...

A process of producing pharmaceutical composition comprising l-(4- chlorobenzhydryl)-4-ethyl-[2'[4"-(2-hydroxybenzhydryl]piperidine] piperazine (compound l)-hydrochloride 5% to 15% w/w, lactose IP 55% to 75% w/w, Starch IP 15% to 25% w/w, Magnesium stearate IP 1% to 2% w/w, Colloidal Silicon dioxide IP 0.5% to 1% w/...

The present invention describes Moxifloxacin as prepared by process claimed in our main application number 175/MUM/2003 dated 7th February 2003. This application also relates to pharmaceutical formulations of the Moxifloxacin, as prepared by process claimed in our main patent application as above. ...

An improved pharmaceutical dispensing aid such as a metered dose inhaler device comprising a transparent canister made of polycarbonate polymer is disclosed. The canister is configured to contain one or more active pharmaceutical ingredients, one propellant or a mixture of propllants along with any other pharmaceuti...

A process for making optically pure (R) and (S) salbutamol comprises obtaining the (R) or (S) isomer of either salbutamol or a salbutamol precursor in substantially optically pure form by resolving a racemic or optically impure mixture of enantiomers of salbutamol or of said precursor with either (L) or (D) tartaric...

The present invention relates to a process for preparing glatiramer base or a pharmaceutically acceptable salt thereof comprising: polymerizing a mixture of N-carboxyanhydride of L-alanine, N- carboxyanhydride of y-benzyl L-glutamate, N-carboxyanhydride of y-benzyl L- tyrosine and N- carboxyanhydride of N-trifluroac...

The present invention relates to a solid pharmaceutical composition for prophylaxis and/or treatment of viral infections and a process for manufacturing the same thereof

Crystalline Form (IV) of doxazosin mesylate, a process for its preparation and uses thereof.

The invention relates to pharmaceutical composition containing a combination of atazanavir and ritonavir, method of making them, and their use in medicine.

The present invention discloses substantially pure gadopentetate dimeglumine salt and improved processes for the preparation of substantially pure gadopentetate dimeglumine salt.

N/A

NOT SUBMITTED

The present invention relates to an antiretroviral composition comprising immunomodulators and anti-retroviral agents for the prevention, treatment or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection.

The invention discloses a process for preparing substantially pure deferasirox or a pharmaceutically acceptable salt thereof which process comprises reacting 2-hydroxy-N-(2-hydroxybenzoyl)benzamide with inorganic acid salt of 4-hydrazinobenzoic acid in presence of an acid in a suitable solvent. ...

The present invention relates to a dose counter. Particularly, but not exclusively, the invention relates to a dose counter for use with a Metered Dose Inhaler (MD1). The dose counter comprises a rotary counting element (26) and an actuator (2). The actuator (2) is movable relative to the rotary counting element (26...

A pharmaceutical aerosol composition comprising at least one hydrofluoroalkane propellant; at least one active agent complexed with an adjuvant; and, optionally, at least one pharmaceutically acceptable excipient.

The present invention provides a process for preparing methyl 5-acetamido-4-amino-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (V), which process comprises reducing methyl 5-acetamido-4-azido-6-(1,2,3-triacetoxypropyl)-5,6-dihydro-4H-pyran-2-carboxylate (IV) in the presence of a reducing agent selec...

A topical composition comprising: fipronil or a pharmaceutically acceptable salt thereof; at least one surfactant and at least one crystallization inhibitor for the treatment and protection of animals which are infested with parasites.

The present invention relates to stable and improved pharmaceutical compositions of atorvastatin calcium. There is also provided a process for preparing a formulation and use thereof in the treatment and / or prevention of physiological conditions based on atorvastatin calcium such as hyperlipidemia, hypercholestero...

Disclosed herein is an improved process for the preparation of 2-((l,3-dioxo-l,3-dihydro-isoindol-2-yl)methyl)-l-phenyl-cyclopropane carboxylic acid diethylamide of formula I, which comprises reacting 2-(( 1,3-dioxo-1,3-dihydro-isoindol-2-yl)methyl)-1 -phenyl-cyclopropane carboxylic acid of formula (II) with diethyl...

The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine, festinavir and nevirapine. to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses, especially acquired immune deficie...

The invention relates to various new polymorphic forms of manidipine and pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of the polymorphic forms of manidipine and pharmaceutically acceptable salts thereof.

The present invention relates to a pharmaceutical composition comprising arformoterol and fluticasone furoate (preferably for once daily administration), to a process for preparing such a composition and to the use of such a composition for the treatment treatment and/or prevention of respiratory, inflammatory or ob...

The present invention relates to a process for the preparation of substantially pure nateglinide of formula (I), substantially free from the cis-isomer and L-enantiomer and preparation of enantiomerically pure nateglinide form B, directly from the hydrolysis of a (-)-N-(trans-4-isopropylcyclohexyl-1-carbonyl)-D-phen...

A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation be...

A complex comprises pemetrexed and a coformer. A pharmaceutical composition comprises a complex of pemetrexed and a co-former and one or more pharmaceutically acceptable excipients.

The present invention relates to a process for the preparation of Compound (A): wherein the process comprises contacting atazanavir base (Compound (II)) with sulphuric acid in a combination of two or more solvents and isolating compound (A). The present invention also relates to substantially pure Compo...

Disclosed herein is a pharmaceutical composition for rectal administration comprising fidaxomicin optionally with one or more pharmaceutically acceptable excipients, useful in the treatment of infections caused by Clostridium difficile and also disclosed herein a process for preparation thereof. ...

N/A

N/A

A pharmaceutical composition comprises tibolone, a water-solute starch and optionally a further pharmaceutical acceptable carrier. Preferred compositions comprise an inclusion complex of tibolone and a water-soluble starch, in particular cyclodextrin. A process for making a tablet comprising a composition of the inv...